2022 Heatwave Struck Off Surgery in Fifth of UK Hospitals

The 2022 summer heatwave resulted in a fifth of UK hospitals being forced to cancel operations during the three days when temperatures soared, a new study reveals.

Had the high temperatures continued, a further third of hospitals would have had to cancel surgery, as NHS buildings are not set up to withstand dangerously high temperatures.

The team surveyed surgeons, anaesthetists, and critical care doctors working during the heatwave of 16 – 19 July 2022.

They received 271 responses from 140 UK hospitals with one in five respondents (18.5%) reporting the heatwave resulted in elective surgery being cancelled. A further third (35.1%) anticipated that cancellations would have been likely had the heatwave continued.

Factors contributing to heatwave-related cancellations included staff shortages (35.8% of respondents), unsafe theatre environments (30.3%), and bed shortages (22.1%).

Surgical services were poorly prepared for heatwaves with ambient temperature uncontrollable in 41.0% of operating theatres. Most hospitals which responded (85%) lacked ‘summer pressure’ plans to maintain elective surgical safety and capacity. Over a third of respondents (35.4%) reported making adaptations to maintain the routine surgical activity during the heatwave.

Co-author Mr James Glasbey, NIHR Doctoral Research Fellow in Global Surgery at the University of Birmingham, commented: “Even short heatwaves may result in widespread disruption to surgical services in the UK. The likelihood of extreme weather events is growing – we could find ourselves in both a ‘winter’ and ‘summer’ stress situation within the next few years.

“As hospitals tackle post-COVID surgery backlogs, they must consider how to safeguard against further climate change-related disruption to the delivery of surgical services. This should be included in the preparation of ‘summer pressure’ plans to improve the resilience of elective surgery services.”

Supported by a National Institute for Health Research (NIHR) Global Health Research Unit Grant, the GreenSurg Collaborative, led by researchers at the University of Birmingham, published their findings in a letter to British Journal of Surgery.

The researchers discovered that hospitals adopted several strategies during the heatwave to cushion the impact of rising temperatures on surgical patients. These included delayed discharge of high-risk patients, changes to surgical teams, selecting lower risk patients to have surgery, and restricting surgical activity to day-cases.

Some hospitals also introduced longer staff breaks, gave extra fluids to patients admitted, and started surgeries earlier in the morning when temperatures were lower.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”